Close Menu

NEW YORK – The combination of Bristol Myers Squibb's anti-PD-1 inhibitor nivolumab (Opdivo) and its anti-CTLA-4 therapy ipilimumab (Yervoy) demonstrated modest activity in metastatic, castration-resistant prostate cancer (mCRPC) patients, according to recently published preliminary data from the CheckMate-650 trial.

However, exploratory biomarker analysis in the same study suggested that patients with higher tumor mutational burden may potentially derive greater benefit from the regimen than those with lower TMB levels and should be investigated further.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.


In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.